A recent PharmaTimes analysis highlights how GLP-1 drugs are reshaping pharmaceutical manufacturing under intense time-to-market pressure and rising investment in production capacity, particularly in the US. The report shows that fragmented systems, regulatory tightening, and AI adoption are increasing hidden
